# The dopaminergic system in neurodevelopment: preclinical models of neurodevelopmental disorders and susceptibility to neurodegeneration

**Authors:** Michele Santoni, Andrea Mastio, Marco Pistis, Claudia Sagheddu

PMC · DOI: 10.3389/fncel.2026.1782731 · Frontiers in Cellular Neuroscience · 2026-02-23

## TL;DR

This paper explores how early disruptions in the dopamine system during brain development can lead to disorders and later neurodegeneration, using preclinical models.

## Contribution

The paper highlights how genetic and environmental factors during development affect dopamine system maturation and future vulnerability to neurodegeneration.

## Key findings

- Early-life dopamine disruptions may increase risk for neurodevelopmental and neurodegenerative disorders.
- Midbrain dopamine neurons are particularly vulnerable to developmental and aging-related stressors.
- Current treatments lack innovation, suggesting a need to target developmental mechanisms early.

## Abstract

The dopaminergic system plays a pivotal role in neurodevelopment, guiding the formation and refinement of neural circuits underlying salience attribution, cognition, reward and aversion. Its maturation extends from prenatal life through adolescence and may be influenced by genetic and environmental factors. Evidence from preclinical models suggests that perturbations during these sensitive windows may alter neurodevelopmental trajectories toward maladaptive outcomes, increasing vulnerability to neurodevelopmental disorders. This mini-review synthesizes findings from animal models to examine how physiological dopaminergic maturation might be shaped by genetic, as well as environmental, factors. We discussed maternal immune activation, prenatal cannabis exposure, and genetic models directly targeting dopaminergic function, all of which underscore the critical role of dopamine dysregulation in shaping neurodevelopmental outcomes. Beyond neurodevelopmental disorders, we extend this framework to newly emerging evidence concerning how early-life dopaminergic perturbations may influence dopamine system resilience and predispose individuals to accelerated cognitive decline and neurodegenerative disorders. Midbrain dopamine neurons exhibit intrinsic vulnerabilities that may render them especially sensitive to cumulative developmental and aging-related stressors and may serve as early predictors of disease. Finally, we discuss the therapeutic implications, emphasizing the limited mechanistic innovation in current pharmacological treatments and the growing need to target upstream or convergent developmental mechanisms in order to modify disease trajectories before overt dopaminergic dysfunction becomes established.

## Full-text entities

- **Genes:** Th (tyrosine hydroxylase) [NCBI Gene 25085] {aka The}, Slc6a3 (solute carrier family 6 member 3) [NCBI Gene 24898] {aka Dat1}, Snca (synuclein alpha) [NCBI Gene 29219]
- **Diseases:** ADHD (MESH:D001289), psychosis (MESH:D011618), neuropsychiatric phenotypes (MESH:C000631768), infection (MESH:D007239), neurodevelopmental dysfunction (MESH:D065886), Rett syndrome (MESH:D015518), brain dysfunction (MESH:D001927), Dopaminergic (MESH:D009422), behavioral and cognitive impairments (MESH:D003072), MIA (MESH:D000079262), neurodevelopmental disorders (MESH:D002658), compulsive stereotypies (MESH:D000073932), synaptic dysfunction (MESH:C536122), neurodevelopmental alterations (MESH:C535809), amyloid (MESH:C000718787), dementias (MESH:D003704), deficits in cognitive performance, attentional control, and impulse regulation (MESH:D007174), schizophrenia (MESH:D012559), Impairments in the VTA (MESH:D006555), Alzheimer's disease (MESH:D000544), substance abuse (MESH:D019966), neuropsychiatric disorders (MESH:D001523), mitochondrial dysfunction (MESH:D028361), Parkinson's disease (MESH:D010300), autism spectrum disorder (MESH:D000067877), gestational inflammation (MESH:D007249), neurodegeneration (MESH:D019636), hyperactivity (MESH:D006948), Fragile X syndrome (MESH:D005600), dopaminergic dysregulation (MESH:D021081), neurobehavioral deficits (MESH:D019954)
- **Chemicals:** methylphenidate (MESH:D008774), Ca2+ (-), cannabinoid (MESH:D002186), dopamine (MESH:D004298), endocannabinoid (MESH:D063388), lipid (MESH:D008055), Delta9-tetrahydrocannabinol (MESH:D013759), amphetamine (MESH:D000661), acetylcholine (MESH:D000109)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989], Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967975/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12967975/full.md

## References

88 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967975/full.md

---
Source: https://tomesphere.com/paper/PMC12967975